{
  "id": "gensight-biologics-shareholders-approve-most-resolutions-at-extraordinary-meeting",
  "title": "GenSight Biologics shareholders approve most resolutions at extraordinary meeting",
  "summary": "GenSight Biologics S.A., a clinical‑stage gene therapy company focused on retinal neurodegenerative diseases and central nervous system disorders, announced the results of its Extraordinary General Meeting held on January 28, 2026. Shareholders approved all resolutions presented, except for Resolution 8 concerning a reserved capital increase, which was rejected. The company said the outcome does not affect its ability […] The post GenSight Biologics shareholders approve most resolutions at extraordinary meeting appeared first on Longevity.Technology.",
  "url": "https://longevity.technology/news/gensight-biologics-shareholders-approve-most-resolutions-at-extraordinary-meeting/",
  "source": "Longevity.Technology",
  "author": null,
  "category": "news",
  "publishedAt": "2026-01-31T08:46:06.000Z",
  "fetchedAt": "2026-02-04T10:49:05.817Z",
  "relevanceScore": 0.2,
  "matchedKeywords": [
    "longevity"
  ],
  "relatedProducts": [],
  "type": "web",
  "savedAt": "2026-02-04T10:49:05.888Z"
}